Invivyd FY2022 net loss $241.3M; advancing VYD222 mAb into clinic

Invivyd, Inc.

Cash, cash equivalents and marketable securities $372M as of Dec 31, 2022, expected to fund operations into H2 2024.
Net loss $241.3M ($2.23 per share) for FY2022 vs $226.8M ($5.32 per share) in FY2021.
R&D expenses $183.6M, down slightly from $190.4M in FY2021.
Advancing VYD222 into Phase 1 clinical trial in Q1 2023; in vitro data shows neutralizing activity against XBB.1.5.
Appointed Jeremy Gowler as COO and promoted Pete Schmidt to CMO.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Invivyd, Inc. reported the year ended December 31, 2022 results: net income $241.3 million.

Period: the year ended December 31, 2022
Net income: $241.3 million
Result: reported results

Exact text from the filing

Net loss was $241.3 million for the year ended December 31, 2022

View on SEC.gov

Browse all earnings releases →

Invivyd, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-23-077876

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.